Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Chemmedchem|December 7, 2018
Discovery of Affinity-Based Probes for Btk Occupancy AssaysHui Qiu, Richard Caldwell, Lesley Liu-Bujalski, et al.Chemmedchem|September 28, 2021
Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory ActivityHui Qiu, Zahid Ali, Julian Bowlan, et al.Clinical Immunology (Orlando, Fla.)|January 29, 2016
Btk inhibition treats TLR7/IFN driven murine lupusAndrew T Bender, Albertina Pereira, Kai Fu, et al.Bioorganic & Medicinal Chemistry Letters|September 24, 2018
Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitorsHui Qiu, Lesley Liu-Bujalski, Richard D Caldwell, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 24, 2012
Interaction of Ets-1 with HDAC1 represses IL-10 expression in Th1 cellsChoong-Gu Lee, Ho-Keun Kwon, Anupama Sahoo, et al.JCI Insight|July 19, 2022
Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinibLiza Rijvers, Jamie van Langelaar, Laurens Bogers, et al.Frontiers in Immunology|June 7, 2014
Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical StudiesPhilipp Haselmayer, Montserrat Camps, Mathilde Muzerelle, et al.Bioorganic & Medicinal Chemistry|May 1, 2021
Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitorsHui Qiu, Zahid Ali, Andrew Bender, et al.Journal of Medicinal Chemistry|August 2, 2019
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological DiseasesRichard D Caldwell, Hui Qiu, Ben C Askew, et al.Pageof 3